Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024


DUBLIN, April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations.

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through June 12, 2024.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
[email protected]
650-808-4045

 

SOURCE Theravance Biopharma, Inc.


These press releases may also interest you

at 08:56
Earnix and Exavalu Partner to Help P&C Carriers Modernize Pricing and Rating Flexibility
Earnix, the leading global provider of AI-based SaaS pricing and rating solutions for financial services, and Exavalu, a leading global insurance digital advisory and system integration consulting firm, today announced a strategic partnership to...

at 08:50
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership
Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities. The partnership...

at 08:50
CloudMD Announces Go-Private Transaction with CPS Capital
CloudMD Software & Services Inc. (the "Company" or "CloudMD"), an innovative health services company transforming the delivery of care, and CPS Capital ("CPS Capital"), an entrepreneurial investment firm partnering with businesses and teams to...

at 08:47
Directions Inc President and CEO Jim Lane Announces Retirement
Directions Inc announced today that Jim Lane, President and Chief Executive Officer, will retire on December 31, 2024, after nine years of leading the firm through tremendous growth and transformation. Following an internal selection process and...

at 08:46
ALIVE Podcast Network: Celebrates Mental Health, Women, and Wellness with Its Richest Lineup Yet
As we prepare our abs and playlists for poolside vibes, the ALIVE Podcast Network is loading its app with dope conversations to have you locked and loaded for cookout debates ? from the intense Kendrick vs. Drake showdown to pressing discussions on...

at 08:45
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
Vanda Pharmaceuticals Inc. (Vanda) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the...

More news about Health...


News published on and distributed by: